Efferon secures €2.5M to grow blood purification platform

Biotech
company Efferon has raised €2.5 million in a seed funding round led by private
investors from the DACH region to support the European commercial expansion of
Efferon LPS, its hemoadsorption device approved for the treatment of sepsis and
septic shock.

Efferon
develops multimodal hemoadsorption therapeutic devices designed to remove
endotoxins and inflammatory mediators directly from the bloodstream. The
company’s product portfolio includes Efferon LPS, a hemoadsorption cartridge
combining endotoxin and cytokine adsorption, and Efferon NEO, a version
developed for pediatric use.

Use
of Efferon devices can help reduce ICU treatment costs by supporting faster
stabilisation of septic shock and reducing time spent on mechanical ventilation
and intensive care treatment, according to the company.

Systemic
inflammation plays a role not only in acute critical illness, but also across a
range of chronic and age-related diseases. Efferon says its hemoadsorption
platform is designed to support future applications beyond intensive care and
sepsis treatment.

According
to Dima Romashin, CEO and co-founder of Efferon, sepsis causes more than 11
million deaths annually worldwide, yet continues to receive significantly less
research attention and funding than other major diseases such as cancer.

We’re
not just bringing a product to market – we’re fighting to put sepsis where it
belongs: at the top of the world’s medical agenda.

Efferon
recently received CE MDR certification for Efferon NEO, making it the first
hemoadsorption device in Europe approved for neonatal and pediatric patients
with sepsis and septic shock. The approval was supported by results from the
multicentre LASSO NEO study, which evaluated targeted endotoxin and cytokine
removal in patients aged between one month and 18 years.

The
company says its technology has already been used in more than 25,000
treatments across over 40 countries, including Germany, the United Kingdom,
Australia and Saudi Arabia.

The new
funding will support the construction of a new EU production facility for Efferon
LPS and the expansion of the company’s manufacturing capacity to meet growing
demand for its blood purification therapy for sepsis and septic shock.